Evidence map›Paper›PMID 39682278›Full record

ArticleCancers2024

Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity.

Filomena Emanuela Laddaga, Michele Telegrafo, Carmela Garzillo, Alba Fiorentino, Angela Sardaro, Stefano Martinotti, Marco Moschetta, Francesco Gaudio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Filomena Emanuela LaddagaHematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Michele TelegrafoInterdisciplinary Department of Medicine (DIM), Section of Radiology and Radiation Oncology, University of Bari, 70124 Bari, Italy.
Carmela GarzilloInterdisciplinary Department of Medicine (DIM), Section of Radiology and Radiation Oncology, University of Bari, 70124 Bari, Italy.
Alba FiorentinoDepartment of Medicine and Surgery, LUM University "Giuseppe Degennaro", Casamassima, 70010 Bari, Italy.
Angela SardaroInterdisciplinary Department of Medicine (DIM), Section of Radiology and Radiation Oncology, University of Bari, 70124 Bari, Italy.
Stefano MartinottiDepartment of Medicine and Surgery, LUM University "Giuseppe Degennaro", Casamassima, 70010 Bari, Italy.ORCID 0000-0001-7672-891X
Marco MoschettaInterdisciplinary Department of Medicine (DIM), Section of Radiology and Radiation Oncology, University of Bari, 70124 Bari, Italy.
Francesco GaudioDepartment of Medicine and Surgery, LUM University "Giuseppe Degennaro", Casamassima, 70010 Bari, Italy.ORCID 0000-0002-7817-1665

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin lymphoma (HL) treatment has dramatically improved, with high survival rates in early stages. However, long-term survivors face an increased risk of secondary cancers, particularly breast cancer (BC), which emerge as a leading cause of mortality decades after therapy.

Indexed as

breast cancerHodgkinlate toxicitylong term survivorsradiotherapy

Identifiers

PMID39682278
PMCPMC11639875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.